Mutations of the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause of Parkinson's disease (PD) and are associated with pleiomorphic neuropathology. We hypothesize that LRRK2 mediates its pathogenic effect through alternative splicing of neurodegeneration genes. Methods used in this study included western blotting analysis of subcellular protein fractions, exon-array analysis of RNA from cultured neuroblastoma cells transfected with LRRK2 expression vectors, and reverse-transcription polymerase chain reaction (RT-PCR) of RNA from cultured cells and postmortem tissue. Overexpression of the LRRK2 G2019S mutant resulted in a significant (2.6-fold; P 5 0.020) decrease in nuclear transactive response DNA-binding protein 43 levels. Exon-array analyses revealed that wild-type LRRK2 had a significant effect on the expression of genes with nuclear (P < 10 222 ) and cell-cycle functions (P < 10 215 ). We replicated changes in gene expression in 30% of selected genes by quantitative RT-PCR. Overexpression of LRRK2 resulted in the altered splicing of two genes associated with PD, with an increased inclusion of exon 10 of microtubule-associated protein tau (1.7-fold; P 5 0.001) and exon 5 of the alpha-synuclein (SNCA) gene (1.6-fold; P 50.005). Moreover, overexpression of LRRK2 (G2019S) and two mutant genes associated with neurodegeneration, TARDBP (M337V) and FUS (R521H), were associated with decreased inclusion out of the dystonin (DST) 1e precursor exons in SK-N-MC cells. Altered splicing of SNCA (1.9-fold; P < 0.001) and DST genes (log 2 2.3-fold; P 5 0.005) was observed in a cohort of PD, compared with neurologically healthy, brains. This suggests that aberrant RNA metabolism is an important contributor to idiopathic PD. V C 2012 Movement Disorder Society
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PD (OMIM 168600) is the second-most common progressive neurodegenerative disorder, affecting approximately 2% of the population at 65 years of age. 1 The disease is characterized clinically by a combination of motor symptoms, including tremor, bradykinesia, and rigidity. 1 Neuropathologically, the disease is characterized by severe loss of dopaminergic neurons in the substantia nigra and cytoplasmic inclusions comprised mainly of a-synuclein, known as Lewy bodies. 2 The leucine-rich repeat kinase (LRRK2) gene codes for a large 2,527-amino-acid, guanosine triphosphatase/kinase protein 3 that has multiple physiological roles. [4] [5] [6] LRRK2 mutations cause $7% of familial PD cases, 7 and the most common mutation is a glycine for serine amino-acid substitution at codon position 2019 (G2019S). 8 Though most patients with LRRK2 mutations have typical Lewy body pathology, some cases have substantia nigra degeneration alone (one with transactive response DNA-binding protein 43 [TDP-43] immunopositive inclusions), whereas others have tau-immunopositive inclusions consistent with frontotemporal lobar degenerations (FTLDs). 9 These observations suggest that LRRK2 serves as an upstream central integrator of multiple cell-signaling pathways. 10 A significant proportion of the human genome is alternatively spliced, a process that allows individual genes to express multiple protein isoforms with diverse functions. 11 There is evidence that the neurodegenerative process involves the disruption of mechanisms regulating messenger RNA metabolism and alternative splicing. First, mutations have been identified in the TDP-43 (TARDBP) and fused in sarcoma (FUS) genes in familial forms of motor neuron disease. 12 These genes code for heterogeneous nuclear ribonucleoprotein (hnRNP), which is implicated in exon splicing and transcription regulation. 12 Moreover, a link between environmental insults and alternative splicing has been identified. The treatment of neuronal cells with paraquat, a pesticide to generate models of PD, has been shown to decrease the exon inclusion of a number of genes. 13 Though many gene-array studies on the pathogenic role of LRRK2 have focused on changes in overall gene expression, we present data from exon-array analysis from cells overexpressing LRRK2 wild-type (WT) or G2019S mutant protein that demonstrate the effects of LRRK2 on alternative splicing as well as the association of the G2019S mutation with altered splicing of key neurodegenerative genes.
Materials and Methods

Expression Constructs
Expression constructs with WT and G2019S mutant LRRK2 complementary DNAs (cDNAs), the TARDPB (M337V) cDNA, and FUS (R521H) cDNA were made as previously reported.
14-16
Determination of TDP-43 Levels and Subcellular Localization Subcellular levels of TDP-43 protein were determined by western blotting, as previously reported. 17 
Lipid Raft Assay
Lipid raft and nonraft fractions were prepared from cells according to their solubility in detergent, as described previously. 18 
Exon-Array Analyses
Recombinant vectors were transfected into the human neuroblastoma line, SK-N-MC, and left for 48 hours before total RNA extraction. Microarray analysis, using the human GeneChip Exon 1.0 ST Arrays (Affymetrix, Santa Clara, California, USA), was performed by the Ramaciotti Center for Gene Function Analyses (University of New South Wales, Sydney, New South Wales, Australia).
SYBR Semiquantitative Real-Time ReverseTranscription Polymerase Chain Reaction Validation of Gene Expression
Polymerase chain reaction (PCR) primers for the validation of each candidate gene were designed to span exon/exon boundaries to minimize the effects of genomic DNA contamination. The complete set of primers is listed in Supporting Table 1 .
RT-PCR Validation of Alternative Splicing
PCR primers for each candidate gene were designed to flank the alternatively spliced exon. The complete set of primers is listed in Supporting Table 2 .
PD and Neuropathologically Healthy Control Autopsy Cases for Comparison
Brain tissue (i.e., amygdala) from 10 nondemented PD cases (7 males and 3 females; age, 79 6 2.7 years; postmortem delay, 9 6 2.9 hours) and 8 controls (4 males and 4 females; age, 86 6 1.4 years; postmortem delay, 11 6 1. 
Statistical Analysis
Mean differences in quantitative measures were compared with the use of the two-tailed Student's t test. Differences in proportions were determined by chi-square statistics. P values from validation experiments were corrected using the false-discovery-rate algorithm. 19 Mean and standard error of the mean (SEM) are given for all variables. Regression analyses were used to examine the relationship between alternative splicing levels, sex, age, and postmortem delay.
Results
Overexpression of WT and Mutant LRRK2
Affect Subcellular Levels of TDP-43
A feature of the neuropathology associated with several LRRK2 mutations is cytoplasmic TDP-43-immunopositive inclusions. 9 This led us to examine whether LRRK2 has a role in regulating the subcellular localization of TDP-43. Transfection of LRRK2 cDNA expression constructs resulted in overexpression of the LRRK2 protein by approximately 12-fold (as determined by real-time reverse
transfected SK-N-MC cells, relative to cells transfected with the LacZ construct (data not shown). Cells transfected with LRRK2 G2019S mutant constructs resulted in a significant (2.6-fold; P ¼ 0.020) decrease in nuclear TDP-43 levels, compared to LacZ-transfected cells (Fig. 1A,B) . However, no significant changes were observed for TDP-43 in cytoplasmic fractions (Fig. 1A,B ). Cells transfected with WT LRRK2 construct did not result in significant changes of TDP-43 in the cytoplasmic or nuclear fractions (Fig. 1A,B) , relative to the LacZ control. The LRRK2 protein has been previously shown to localize to lipid rafts, which are glycolipoprotein microdomains within cellular membranes and are thought to mediate a number of processes, including protein trafficking. 5 We examined whether the WT and G2019S mutant LRRK2 proteins colocalize to lipid rafts by western blotting after the extraction of lipid raft and nonraft components (Supporting Materials; Fig. 1C ). We confirmed that both WT and mutant proteins localize mainly to the lipid raft fractions, as previously reported. 5 However, we did not observe any difference in the ability of the G2019S mutant to alter its affinity with lipid rafts after we normalized protein levels using the Gai-2 lipid-raft-specific marker and the calnexin lipid non-raft-specific marker 18 ( Fig. 1C) , suggesting that the alterations in nuclear TDP-43 levels were not mediated by a change in lipid raft localization of the mutant protein.
Overexpression of WT and Mutant LRRK2 Resulted in Significant Overlap in Number of Differentially Expressed Genes
We compiled a list of genes that are differentially regulated by the overexpression of either WT or G2019S mutant LRRK2 cDNAs, compared to LacZ control (Supporting Data 1 in Supporting Materials). We observed that the overexpression of WT LRRK2 affected the regulation of 20-fold more genes than mutant LRRK2, despite similar levels of transgene expression. Biological pathway analyses 20 showed that the WT LRRK2 gene list showed a significant enrichment of genes encoding nuclear proteins (P < 2 Â 10
À22
) and genes involved in cell cycle (P < 6 Â 10 À16 ) and cell division (P < 2 Â 10
À15
). Conversely, no significant enrichment of any biological pathways was observed for the LRRK2 mutant gene list. We chose nine target genes for validation by real-time RT-PCR (Table 1) . These were genes that were specific to the WT LRRK2 gene list (e.g., CHORDC1, CHMP2B, TARDBP, BRCA1, MAPK8, DICER1, and TMEM100), which are genes known to be involved in neurodegeneration (e.g., TARDBP 12 and CHMP2B
21
), and two genes whose expression were discordantly regulated by the WT and mutant LRRK2 (e.g., NDUFA4 and CD1C). We were able to significantly replicate three genes (TARDBP, transmembrane protein 100 [TMEM100], and DICER1) in which the changes in direction of gene expression were also consistent with the microarray data ( Table 1) . Of interest, we were able to validate a significant effect of WT LRRK2 (log 2 3.2-fold; P ¼ 0.005) on the expression of DICER1, a key regulator of microRNA biogenesis. 22 Overexpression of Mutant LRRK2 Is Associated With Altered Splicing of Two Major PD Genes
We also compiled a list of genes whose exons were differentially spliced by the overexpression of WT or mutant LRRK2 (Supporting Data 2 in Supporting Materials) cDNAs. We observed that WT LRRK2 overexpression resulted in a 2-fold increase in the number of differentially spliced genes, compared to the mutant protein. Moreover, there was a significant increase in the proportion of genes that were differently spliced versus those that were differentially expressed in cells transfected with the G2019S mutant (760:80), compared to WT LRRK2 (1,678:1,678) (Pearson's chi square ¼ 452; P < 0.0001) (Fig. 2A) . Biological pathway analyses did not reveal any Chemiluminescent band intensities were quantified, and the levels of cytoplasmic (grey columns) and nuclear (black columns) TDP-43 proteins are presented relative to the LacZ control transfection. Mean and SEM from five transfections. Significance of P < 0.05 is indicated (*). (C) Western blotting analysis of lipids from raft and nonraft fractions show that both the WT and G2019S LRRK2 protein did not differ markedly in their distribution between raft and nonraft fractions. Gai-2 (raft specific) and calnexin (nonraft specific) were used to normalize protein levels. 
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significant enrichment for the WT or mutant LRRK2 gene lists. Two genes were chosen from the exon list for validation, with an emphasis placed on a top hit (e.g., CNIH4) and gene involved in the regulation of cell death (FAM188A). 23 Genes were validated by RT-PCR, followed by gel electrophoresis, to visualize products corresponding to the inclusion or exclusion of the candidate exon. This allowed us to measure both splice isoforms from each sample as a single reaction and to normalize for differences in sample concentration. Cells transfected with LRRK2 G2019S mutant cDNA resulted in a significant (1.3-fold; P ¼ 0.007) increase in the inclusion of exon 3 of the cornichon homolog 4 (CNIH4) gene (Fig. 2B,C) . No significant effects were observed for the WT LRRK2 cDNA (Fig. 2B,C) or FAM188A gene (data not shown).
We then proceeded to examine previously validated alternatively spliced exons from two major PD genes: the microtubule-associated protein tau (MAPT) and alpha-synuclein (SNCA) genes. 24 Similar to the CNIH4 gene, cells transfected with LRRK2 G2019S mutant cDNA resulted in a significant (1.7-fold; P ¼ 0.001) increase in splicing of exon 10 of MAPT, but had no effect on the inclusion of exon 5 of the SNCA 
gene (Fig. 2B,C) . In contrast, cells that overexpressed WT LRRK2 significantly increased (1.6-fold; P ¼ 0.005) inclusion of exon 5 of SNCA, but had no effect on the alternative splicing of MAPT (Fig. 2B,C) .
Dysregulated Alternative Splicing Is a Common Effect in PD Brains
TARDBP and FUS genes are two major neurodegenerative genes that code for hnRNPs involved in the gene expression and RNA metabolism. 12 Our western blotting data suggest that LRRK2 might act to control the subcellular levels of TDP-43 ( Fig. 1) and thus may act, in part, through the same pathogenic pathway on gene expression and RNA metabolism. To identify common effects of the LRRK2 (G2019S), TARDBP (M337), and FUS (R521H) mutants, we compiled a list of differentially expressed genes (Supporting Data 1 in Supporting Materials) and spliced exons (Supporting Data 2 in Supporting Materials) in SK-N-MC cells overexpressing these mutant cDNAs. Thirty-one genes appear to be consistently affected by the overexpression of mutant LRRK2, TARDBP, or FUS (Fig. 3A) . Biological pathway analysis did not reveal any significant enrichment of pathways from this gene list. Eight genes (ASPM, DPY19L4, MPHOSPH10, NLGN1, PRKaR2B, RAB1A, SMAD2, and VANGL1) were chosen from this list for validation by real-time RT-PCR, with an emphasis on genes with neuronal functions (NLGN1 25 and VANGL1
26
) or known interactions with LRRK2 protein (RAB1A 27 ). None of the changes in gene expression were successfully replicated with samples from all three mutant transfection groups.
Of the exons identified as significantly differentially spliced (Supporting Data 2 in Supporting Materials), 244 exons were common to all three mutant gene lists (Fig. 3A) . This represented an enrichment of exons encoded by cytoplasmic proteins (P ¼ 0.010). 20 Four exons from the list (DST, HSP5, PPM1A, and ZNRD1) were chosen for validation based on top hits (HSP5, PPM1A, and ZNRD1) and a gene involved in neurodegeneration (dystonin; DST).
28 Overexpression of all three mutant genes in SK-N-MC cells resulted in an increased inclusion of exon 2 of the HermanskyPudlak syndrome 5 (HSP5) gene (1.7-to 3-fold; P ¼ 0.024 to P ¼ 0.005), compared to the LacZ control (Fig. 3B,C) . A similar effect was observed for the zinc ribbon domain-containing 1 (ZNRD1) gene, in which increased inclusion of exon 2 was observed for cells overexpressing the FUS (R521H) (1.9-fold; P ¼ 0.001) and TARDBP (M337V) (1.6-fold; P ¼ 0.010) mutants (Fig. 3B,C) , compared to LacZ control.
Several Affymetrix exon probes for the DST gene were identified as being significantly affected by the overexpression of the three mutant genes (Supporting Data 2 in Supporting Materials), consistent with the observation that DST undergoes complex alternative splicing to generate multiple protein isoforms. 29 The probe, 2958477, corresponds to the inclusion of exons coding for the DST 1e precursor (RefSeq NM_001723). Overexpression of all three mutants, but not WT LRRK2, decreased the inclusion of the DST 1e precursor-specific exons, compared to lacZ control, with significance reached for LRRK2 (G2019S) (log 2 2-fold; P ¼ 0.001) and FUS (R521H) (log 2 1.3-fold; P ¼ 0.005) mutants (Fig. 3D) .
We proceeded to determine whether the aberrant splicing of DST, MAPT, and SNCA in our cellular model was also observed in postmortem brain tissue of neuropathologically defined PD cases (Supporting Materials; Fig. 4 ). We demonstrated that alternative splicing of SNCA was significantly altered in PD cases, with a 1.9-fold (P < 0.001) decrease in the inclusion of exon 5 of the SNCA gene, compared to neurologically healthy brains (Fig. 4A) . There was also a significant (log 2 2.3-fold; P ¼ 0.005) decrease in the inclusion of the DST 1e precursor-specific exons in PD, compared to neurologically healthy brains (Fig. 4B) . No significant changes in alternative splicing of MAPT were observed in brain tissue (Fig. 4A) . Sex, age, and postmortem delay were not significant predictors of alternative splicing in MAPT, SNCA, or DST (data not shown; P > 0.05).
Discussion
The LRRK2 gene has emerged as one of the most prevalent genetic causes of PD. 7 This is the first study to demonstrate that the LRRK2 gene may have a role in alternative splicing of at least two major PD genes: MAPT and SNCA. Dysfunction in the alternative splicing of MAPT has been shown in genetic forms of FTLD to alter the relative ratios of key splice isoforms crucial for axonal integrity. 30 Similarly, a splice isoform of the SNCA gene lacking exon 5 (Dexon5) had been shown to inhibit proteasomal function and preferentially form aggregates in vitro. 31 In our cellular model, we demonstrated that the overexpression of mutant LRRK2 caused a similar change in MAPT splicing to FTLD. The lack of aberrant splicing of the MAPT gene in our brain cohort (Fig. 4A) was expected (the cases did not have frontotemporal dementia), and suggests that the gene association between PD and MAPT is more the result of gene expression 32 than alternative splicing. Our cellular model also revealed that overexpression of WT LRRK2 increased the alternatively spliced, aggregateforming SNCA Dexon5 isoform, providing a mechanism linking LRRK2 to alpha-synuclein neuropathology. The significant increase in the SNCA Dexon5 isoform in our PD brain tissue (Fig. 4A) is consistent with this mechanism and confirms previous studies. 31 hnRNP proteins, such as TDP-43 and FUS, can interact with the basal splicing protein complex 11 and affect alternative splicing of genes. These proteins can be regulated by growth-factor-dependent kinase phosphorylation. 19 Subcellular fractionation of cells overexpressing LRRK2 demonstrated that the LRRK2 protein was predominantly found in cytoplasmic and lipid raft fractions (Fig. 1C) , indicating that LRRK2 does not act directly on the basal splicing protein complex within the nucleus, but may act indirectly by phosphorylating hnRNPs. It is also unclear whether the G2019S mutant has an altered enzymatic activity or changed ability to bind to these factors, compared to the WT molecule.
Dystonin belongs to the Plakins family of proteins, which function to link cellular cytoskeletal elements with each other and connect them to junctional complexes. 28 Our exon-array data suggest that altered splicing of the DST locus represents a common mechanism by which mutations in TARDBP, FUS, and LRRK2 genes (Fig. 3A,D) may give rise to neurodegeneration (Fig. 3A,D) . Consistent with this observation was that TDP-43 was shown to bind directly to DST transcripts, and depletion of the TDP-43 molecule resulted in increased splicing out of a DST exon. 33 We also demonstrate that there was a significant decrease in the inclusion of the exon encoding the DST 1e precursor splice isoform in PD brain tissue. It still remains to be elucidated what the exact biological role of the 1e precursor isoform is and how alterations in the levels of this splice isoform may contribute to PD.
The main limitation of this study was the use of overexpression of the WT and mutant proteins in transfected neuroblastoma cells as an experimental model, which does not represent the normal level of LRRK2 expression in the brain. Thus, conclusive evidence regarding the effect of LRRK2 on alternative splicing and, more important, whether the G2019S mutation represents a further gain of function in terms of its ability to affect alternative splicing of key neurodegenerative genes ( Fig. 2A) will come from analyses of brain tissue of LRRK2 G2019S mutation carriers. Of further interest is whether the effect on alternative splicing is specific to the G2019S mutation, because mutations have been shown to alter the function of various domains of the LRRK2 protein and are associated with different clinical symptoms and neuropathologies. 9 
Conclusion
In conclusion, we have demonstrated that LRRK2 overexpression in a cellular model alters the isoform expression of key neurodegenerative genes, such as MAPT, SNCA, and DST. The latter two genes were also observed to have altered splicing in postmortem PD brains. This suggests that aberrant RNA metabolism is an important contributor to idiopathic PD.
